Phase II - Ozanezumab (GSK1223249)
Canadian Clinics Recruiting
To be announced. Ask your clinician for details.
Phase II – examining safety and potential efficacy
Route of Administration
Ozanezumab (GSK 1223249) is a drug that targets a protein called Neurite Outgrowth Inhibitor (Nogo-A). It is a monoclonal antibody, which is a substance that the body makes in immunity to prevent the action of a particular protein. Nogo-A blocks neurons from growing toward muscle once the connection has been made. When motor neurons degenerate and the connection becomes weakened, Nogo-A would work against keeping that nerve/muscle contact strong. Increased Nogo-A has been observed in muscle of people with ALS and ozanezumab delayed symptom onset and improved survival in ALS model mice. Thus, it is hoped that it will preserve muscle function and slow the rate of ALS progression in humans.